Virtue Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Virtue Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Sell	455 -66	-13%	-$29.3K	0.03%	324
2026 Q1	$231K	Sell	521 -8	-2%	-$3.73K	0.04%	294
2025 Q4	$239K	Buy	+529	New	+$228K	0.04%	273
2020 Q4	–	Sell	-9,962	Closed	-$2.71M	–	273
2020 Q3	$2.71M	Sell	9,962 -3,695	-27%	-$1.02M	0.67%	32
2020 Q2	$3.96M	Buy	+13,657	New	+$3.7M	0.91%	19
2020 Q1	–	Sell	-2,079	Closed	-$455K	–	208
2019 Q4	$455K	Sell	2,079 -13,241	-86%	-$2.68M	0.13%	156
2019 Q3	$2.6M	Sell	15,320 -2,168	-12%	-$384K	0.86%	38
2019 Q2	$3.21M	Buy	+17,488	New	+$3.06M	1.17%	22
2018 Q4	–	Sell	-25,630	Closed	-$4.94M	–	232
2018 Q3	$4.94M	Buy	25,630 +15,176	+145%	+$2.7M	1.04%	15
2018 Q2	$1.78M	Buy	10,454 +4,201	+67%	+$651K	0.86%	22
2018 Q1	$992K	Buy	6,253 +3,198	+105%	+$522K	0.52%	48
2017 Q4	$458K	Buy	+3,055	New	+$452K	0.26%	106

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Virtue Capital Management's VRTX Position: Q2 2026 in Review

Virtue Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, selling an estimated $29.3K and leaving 455 shares worth $226K. The position accounts for 0.03% of the portfolio, ranked #324.

Virtue Capital Management first reported a position in VRTX in Q4 2017 and has held it in 12 quarters since. The position peaked at $4.94M in Q3 2018. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Virtue Capital Management held 455 shares of Vertex Pharmaceuticals worth $226K as of Q2 2026.
Virtue Capital Management sold 66 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
Vertex Pharmaceuticals made up 0.03% of Virtue Capital Management's portfolio in Q2 2026, its #324 holding.
Virtue Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 12 quarters since.
Virtue Capital Management's Vertex Pharmaceuticals position peaked at $4.94M in Q3 2018.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Virtue Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.